Bone Biologics Corp (BBLGW) Change in Accured Expenses (2010 - 2025)

Bone Biologics (BBLGW) has reported Change in Accured Expenses for 16 consecutive years, with $84803.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Change in Accured Expenses fell 53.66% year-over-year to $84803.0; the TTM figure through Dec 2025 stood at $91025.0 (up 1.39% YoY), while the FY2025 annual figure was $91025.0, up 1.39% from the prior year.
• Change in Accured Expenses climbed to $84803.0 in Q4 2025 per BBLGW's latest filing, from -$70648.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $728839.0 in Q3 2022 and bottomed at -$694689.0 in Q4 2022.
• Historically, Change in Accured Expenses has averaged $3803.6 across 5 years, with a median of $22678.5 in 2021.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 2444.23% — and 2023, when it surged 4131.15%.
• Bone Biologics' Change in Accured Expenses stood at $29634.0 in 2021, then sank by 2444.23% to -$694689.0 in 2022, then jumped by 130.66% to $213017.0 in 2023, then declined by 14.1% to $182985.0 in 2024, then tumbled by 53.66% to $84803.0 in 2025.
• Business Quant data shows BBLGW's Change in Accured Expenses at $84803.0 in Q4 2025, -$70648.0 in Q3 2025, and $155886.0 in Q2 2025.